You can’t beat the diseases
you can’t see.

MRI-Guided Real-time On-table Adaptive
Radiotherapy (ROAR™)

Learn More
MRIdian Locator

We’re Making the Invisible, Visible

Real-time image guidance during beam delivery

Discover MRIdian®

Leveraging on-table MR soft tissue imaging, MRIdian allows oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that’s simply unavailable with conventional IGRT technologies.

Learn More

Clinical Information

Combining the latest innovations in precision radiation delivery, ground-breaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology.

Learn More

ViewRay Reports Third Quarter 2018 Results

ViewRay, Inc. (Nasdaq: VRAY) (“the Company”) today announced financial results for the third quarter ended September 30, 2018. Total revenue of $17.7 million, primarily from 3 revenue units. Received new orders for MRIdian systems totaling $36.2 million.

All News


About ViewRay

A new kind of medical technology company—ViewRay® Inc. designs, manufactures and markets MRIdian, the world’s first MRI-Guided radiation therapy system to image and treat cancer patients simultaneously.

Learn More

Contact Us Today To Learn More Contact

  Global Info


Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy